|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rituximab and alemtuzumabinduce a nonclassic,caspase independent apoptic pathway in lymphoid cell lines and in chronic lymphocytic leukemiacells显示文摘 | Stangl maier M Reis S Hallek M | 2004 | Ann Hematol2004，83，10： | 1 |
| 2 | Phase Ⅰ,first in human trail of BI 836826(an anti-CD37 antibody) in patients(pts) with relapsed/refractory(R/R) chronic lymphocytic leukaemia(CLL)显示文摘 | Stilgenbauer S Aurran Schleinitz T Hallek M | 2015 | Hematol Oncol2015，33，1： | 1 |
| 3 | Recombinant adeno-associated virus(rAAV) vector-mediated contransduction of CD70 and CD80 into human malignant melanoma ceils results in an additive Tcell response显示文摘 | Braun-Falco M Hallek M | 2001 | Arch Dermatol Res2001，293，12： | 1 |
| 4 | Revision of the guideline for diagnosis and therapy of chronic lymphocytic leukemia (CLL) 显示文摘 | Eichorst B Hallek M | 2007 | Best Pract Res Clin Haematol2007，20，3： | 1 |
| 5 | Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells显示文摘 | Stanglmaier M Reis S Hallek M | 2004 | Annals of hematology2004，83，10： | 1 |
| 6 | Addition of ritux-imab to fludarabine and cyclophosphamide in patients with chronic lym-phocytic leukaemia: a randomised,open-label, phase 3 trial 显示文摘 | Hallek M Fischer K Fingerle - Rowson G | 2010 | Lan-cet2010，376，： | 1 |
| 7 | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia:a randomised,open label,phase 3 trial显示文摘 | Hallek M Fischer K Fingerle-Rowson G | 2010 | Lancet2010，376，9747： | 1 |
| 8 | Prognostic factors in chronic lymphocytic leukemia-what do we need to know?显示文摘 | CRAMER P HALLEK M | 2011 | Nat Rev Clin Oncol2011，8，： | 1 |
| 9 | Progress in the use of adeno-associated viral vectors for gene therapy显示文摘 | Buning H Braun-Faleo M Hallek M | 2004 | Cells T Org2004，177，3： | 1 |
| 10 | Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment显示文摘 | Hallek M | 2013 | Am J Hematol2013，88，： | 1 |
| 11 | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia:a randomised,open-label,phase 3trial显示文摘 | HALLEK M FISCHER K FINGERLE-ROWSON G | 2010 | Lancet2010，376，： | 1 |
| 12 | Chronic lymphocytic leukemia:2015Update on diagnosis,risk stratification,and treatment显示文摘 | Hallek M | 2015 | Am J Hematol2015，90，： | 1 |
| 13 | Fludarabine in chronic lymphocytic leukaemia显示文摘 | Eher T Hallek M Engert A | 2006 | Expert Opin Pharmacother2006，7，12： | 1 |
| 14 | Serum thymidine kinase levelsare elevated exhibit diurnal variations in patients with advanced ovarian cancer显示文摘 | Hallek M Touitou Y Levi F | | 0，，： | 1 |
| 15 | Rituximab and alemtuzumab induce a nonclassic,caspase-independent apoptotic pathway in B lymphoid cell lines and in chronic lymphoid cell lines and in chronic lymphocytic leukemia cells显示文摘 | Stanglmaier M Reis S Hallek M | 2004 | Ann Hematol2004，83，10： | 1 |
| 16 | Chronic lymphoctie leukemia: novel prognostic and their relevance for risk -adapted therapeutic strategies 显示文摘 | Montillo M Hamblin T Hallek M | 2005 | Haematologica2005，90，3： | 1 |
| 17 | Muhimodality therapy of colorectal cancer显示文摘 | Hacker U Hallek M Kubicka S | 2010 | Internist(Berl)2010，51，11： | 1 |
| 18 | Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia:a randomised,openlabel,phase 3 trial显示文摘 | Hallek M Fischer K Fingerle-Rowson G | | 0，，9747： | 1 |
| 19 | Progress in the use of adeno-associated viral vectors for gene therapy显示文摘 | Buning H Braun-Falco M Hallek M | 2004 | Cells Tissues Organs2004，77，3： | 1 |
| 20 | Progress in the use of adeno-associated viral vectors for gene therapy显示文摘 | BUNING H BRAUN-FALCO M HALLEK M | 2004 | Cells T Org2004，177，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员